ketorolac and Pregnancy

ketorolac has been researched along with Pregnancy in 33 studies

Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.

Pregnancy: The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.

Research

Studies (33)

Authors

Clinical Trials (14)

Trial Overview

Trial Outcomes

Number of Subjects Experiencing Nausea

Asking patients whether or not they experienced the symptom in the preceding time-frame (NCT02829944)
Timeframe: 2 hours

Number of Subjects Experiencing Nausea

Asking patients whether or not they experienced the symptom in the preceding time-frame (NCT02829944)
Timeframe: 24 hours

Number of Subjects Experiencing Nausea

Asking patients whether or not they experienced the symptom in the preceding time-frame (NCT02829944)
Timeframe: 48 hours

Number of Subjects Experiencing Pruritus

Score reported on a scale of 0-10, with 0 being none and 10 being the worst imaginable (NCT02829944)
Timeframe: 2 hours

Number of Subjects Experiencing Pruritus

Score reported on a scale of 0-10, with 0 being none and 10 being the worst imaginable (NCT02829944)
Timeframe: 24 hours

Number of Subjects Experiencing Pruritus

Score reported on a scale of 0-10, with 0 being none and 10 being the worst imaginable (NCT02829944)
Timeframe: 48 hours

Number of Subjects Experiencing Vomiting

Asking patients whether or not they experienced the symptom in the preceding time-frame (NCT02829944)
Timeframe: 2 hours

Number of Subjects Experiencing Vomiting

Asking patients whether or not they experienced the symptom in the preceding time-frame (NCT02829944)
Timeframe: 24 hours

Number of Subjects Experiencing Vomiting

Asking patients whether or not they experienced the symptom in the preceding time-frame (NCT02829944)
Timeframe: 48 hours

Number of Subjects With Chronic Pain

Phone interview asking patient about presence of pain at incision site (NCT02829944)
Timeframe: 6 months

Number of Subjects With Chronic Pain

Phone interview asking patient about presence of pain at incision site (NCT02829944)
Timeframe: 8 weeks

Opioid Consumption

measured in mg oxycodone equivalents (NCT02829944)
Timeframe: 2 hours

Opioid Consumption

measured in mg oxycodone equivalents (NCT02829944)
Timeframe: 24 hours

Opioid Consumption

measured in mg oxycodone equivalents (NCT02829944)
Timeframe: 48 hours

Pain Score on Movement

Score reported on a scale of 0-10, with 0 being none and 10 being the worst imaginable (NCT02829944)
Timeframe: 48 hours after surgery

Pain Score on Movement (Sitting in Bed From a Supine Position)

Score reported on a scale of 0-10, with 0 being none and 10 being the worst imaginable (NCT02829944)
Timeframe: 24 hours after surgery

Pain Scores at Rest

Score reported on a scale of 0-10, with 0 being none and 10 being the worst imaginable (NCT02829944)
Timeframe: 2 hours

Pain Scores at Rest

Score reported on a scale of 0-10, with 0 being none and 10 being the worst imaginable (NCT02829944)
Timeframe: 24 hours

Pain Scores at Rest

Score reported on a scale of 0-10, with 0 being none and 10 being the worst imaginable (NCT02829944)
Timeframe: 48 hours

Patient Satisfaction With Postoperative Analgesia on a 0-10 Scale

Score reported on a scale of 0-10, with 0 being not at all satisfied and 10 being completely satisfied (NCT02829944)
Timeframe: 48 hours

Postpartum Depression, as Measured by the Edinburgh Postnatal Depression Scale

Patients contacted over the phone completed screening with the EPDS, on a scale of 0-30. A score of over 13 indicate risk for postpartum depression (NCT02829944)
Timeframe: 6 months

Postpartum Depression, as Measured by the Edinburgh Postnatal Depression Scale

Patients contacted over the phone completed screening with the EPDS, on a scale of 0-30. A score of over 13 indicate risk for postpartum depression (NCT02829944)
Timeframe: 8 weeks

Time to First Rescue Analgesic

(NCT02829944)
Timeframe: 48 hours

Cumulative Postoperative Opiate Consumption

Cumulative opiate consumption (IV morphine equivalents) (NCT02487303)
Timeframe: 24 hours

Time Discharge

Time patient meets discharge criteria will be recorded (NCT02487303)
Timeframe: 24 hours postoperative

Time to First Opiate Rescue

Time to first opiate pain medicine requested by patient (NCT02487303)
Timeframe: 48 hours

VAS (Visual Analog Scale)

"Visual Analog Scale (VAS) pain assessment with ambulation. The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between no pain and worst pain. For pain intensity, the scale is most commonly anchored by no pain (score of 0) and pain as bad as it could be or worst imaginable pain (score of 100 [100-mm scale]) ." (NCT02487303)
Timeframe: 24 hours

Apgar Score at 5 Minutes

This is the Apgar score of the newborn collected at 5 minutes. Range is from 0-10, with the higher scores meaning a better outcome. (NCT02922985)
Timeframe: 5 minutes after birth

Hospital Length of Stay

Time to discharge from hospital, measured in hours (NCT02922985)
Timeframe: From time of hospital admission to time of discharge home up to 168 hours.

Need for Respiratory Support

neonate receipt of oxygen by nasal cannula or mechanical ventilation (NCT02922985)
Timeframe: after birth and before hospital discharge

NICU Admission

Rate of admission to the neonatal intensive care unit (NCT02922985)
Timeframe: after birth and before hospital discharge

Number of Opioid Pain Tablets Remaining on Post-operative Day #7 From the Discharge Prescription.

Number of opioid pain tablets remaining on post-operative day #7 from hospital discharge as reported by patients (NCT02922985)
Timeframe: 7 days post delivery

Pain Score at 24 Hours Post-operatively

Pain Score at 24 Hours Post Operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 24 hours post-operatively

Pain Score at 48 Hours Post-operatively

Pain Score at 48 Hours Post-operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 48 hours post-operatively

Pain Score at 6-12 Hours Post Operatively

Pain score at 6-12 hours post-operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 6-12 hours post-operatively

Time to First Administration of Opioid Pain Medication Post Operatively

Time, in hours, to first administration of opioid pain medication post operatively (NCT02922985)
Timeframe: 48 hours post cesarean delivery

Total Opioid Intake in Morphine Milligram Equivalents in the First 48 Hours After Cesarean Delivery (CD)

Every opioid intake by the patient in the first 48 hours after CD will be recorded and quantified in morphine milligram equivalents (NCT02922985)
Timeframe: 48 hours post cesarean delivery

Pain at Time of Osmotic Dilator Placement

"Measure of distance (mm) from the left (no pain) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded at time immediately after osmotic dilator placement. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain." (NCT02354092)
Timeframe: Within 5 minutes of PCB or sham procedure

Pain With Overall Dilator Placement

"Measure of distance (mm) from the left (no pain) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded 15 minutes after osmotic dilator placement. mm=No Pain and 100 mm= worst possible pain. A higher mean score indicates a higher level of pain experienced at this time point." (NCT02354092)
Timeframe: 15 minutes after dilator placement

Pain With Paracervical Block or Sham

"Measure of distance (mm) from the left (no pain) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) recorded at time immediately after last injection for paracervical block OR script for sham injection. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain." (NCT02354092)
Timeframe: Within 5 minutes after baseline

Reported Pain at Baseline

"Measure of distance (mm) from the left (no pain) on the 100-mm visual analog scale (VAS - reflecting magnitude of pain) of pain recorded at baseline prior to the paracervical block or sham block procedure. 0 mm=No Pain and 100 mm= worst possible pain. A higher score indicates a higher level of pain." (NCT02354092)
Timeframe: Baseline, just prior to PCB or sham procedure

Reported Symptoms

fever, chills, vomiting, heavy bleeding/clots (collected without regard to the specific event) (NCT00617097)
Timeframe: end of study (upon discharge from facility after procedure)

Visual Analogue Scale Regarding Satisfaction Level

100-mm Visual Analogue Scale -- minimum: 0 mm (lower satisfaction), maximum: 100 mm (greater satisfaction) (NCT00617097)
Timeframe: end of study (prior to clinic discharge)

Complications

(NCT00617097)
Timeframe: end of study

Level of Pain During Specific Time Intervals Throughout D&C Procedure.

"100-mm Visual Analogue Scale (VAS) during specific time intervals of D&C procedure: minimum: 0 mm (less pain); maximum: 100 mm (more pain)~Time intervals include: basline expected level of pain during procedure, after speculum insertion, at paracervical block injection, after dilation, end of procedure, and 30 minutes after procedure." (NCT00617097)
Timeframe: Baseline, Speculum Insertion, at Paracervical block injection, After dilation, End of procedure, 30 minutes after procedure

VAS (Visual Analogue Scale) Measurement of Pain

The patient marked their pain on a 0 to 10cm visual analogue scale, where 0 cm is no pain and 10 cm is the worst pain ever. (NCT01664559)
Timeframe: Pain with IUD placement, measured immediately after placement

Nulliparous Patients - Subgroup Analysis

"The patient marked their pain on a 0 to 10cm visual analogue scale, where 0 cm is no pain and 10 cm is the worst pain ever.~Prior to injection of study drug, anticipated pain~Pain from study drug injection, measured immediately after injection~Pain from speculum insertion, measured immediately after insertion~Pain with tenaculum placement, measured immediately after placement~Pain with uterine sounding, measured immediately after removal of the sound~Pain at 5 minutes after placement of the intrauterine device~Pain at 15 minutes after placement of the intrauterine device" (NCT01664559)
Timeframe: immediately after each step (see description)

Pain Scores at Other Time Points During and After IUD Placement

"The patient marked their pain on a 0 to 10cm visual analogue scale, where 0 cm is no pain and 10 cm is the worst pain ever.~Prior to injection of study drug, anticipated pain~Pain from study drug injection, measured immediately after injection~Pain from speculum insertion, measured immediately after insertion~Pain with tenaculum placement, measured immediately after placement~Pain with uterine sounding, measured immediately after removal of the sound~Pain at 5 minutes after placement of the intrauterine device~Pain at 15 minutes after placement of the intrauterine device" (NCT01664559)
Timeframe: immediately after each step (see description)

Post-insertion Patient Questionnaire

"Questions assessed in multiple choice format:~Side effects~injection site pain~overall satisfaction with IUD insertion experience~would they still recommend IUD placement to a friend?~significant pain for which they desired acetaminophen prior to leaving the office?" (NCT01664559)
Timeframe: assessed at 15 minutes after IUD insertion

Post-insertion Provider Questionnaire

"The provider will be asked to fill out a multiple choice format questionnaire:~what level training are you?~which IUD was inserted?~what was the purpose of IUD placement?~what was the position of the uterus?~did the IUD placement process require cervical dilation?~were you able to complete the IUD insertion?~was there bleeding from the cervix that required more than 5 min to control?~were there any major complications with the IUD insertion?~did the patient take tylenol prior to leaving the office?" (NCT01664559)
Timeframe: Immediately after IUD placement, on average within 1 hour

Pain With Intrauterine Device (IUD) Placement

Distance (mm) from the left of the 100-mm visual analog scale (reflecting magnitude of pain) recorded at time of IUD Placement. Scale range is from 0mm (no pain) to 100mm (worst pain possible). A lower score (less pain) is considered a better outcome. (NCT02219308)
Timeframe: Moment of IUD insertion

Median Pain Scores for All Time Points

Distance (mm) from the left of the 100-mm visual analog scale of pain at various time points. Scale range is 0mm (no pain) to 100mm (worst pain possible). Lower scores are considered better outcomes. (NCT02219308)
Timeframe: Anticipation of procedure through 5 minutes after IUD placement

Anti-emetic Doses

Total doses of medications to treat pruritus (opioid side-effect) including ondansetron and promethazine. (NCT02509312)
Timeframe: 0 - 24 hours post-partum

Corrected Change in Hct on POD1.

Corrected change in Hct on POD1. Performed by subtracting POD1 Hct from POD0 Hct. Correction for transfusion by further subtracting 3 per unit of pRBC transfused to account for the typical change seen per unit transfused. (NCT02509312)
Timeframe: POD1

Estimated Blood Loss (EBL)

Estimation of blood loss during surgery (NCT02509312)
Timeframe: Immediately post-op

Post-Partum Hemorrhage

Rate of Post-Partum Hemorrhage between groups during the first 24 hours pst-partum. (NCT02509312)
Timeframe: 0 - 24 hours post-partum

Pruritus Doses

Total doses of medications to treat pruritus (opioid side-effect) including diphenhydramine, nalbuphine and naloxone. (NCT02509312)
Timeframe: 0 - 24 hours post-partum

Total Hydromorphone Dose

Total hydromorphone doses in mg in the first 24 hours post-partum. (NCT02509312)
Timeframe: 0 - 24 hours post-partum.

Units of Packed Reb Blood Cell Transfused

Total number of Units of Packed Reb Blood Cell Transfused in intra-op until 24 hours post-partum. (NCT02509312)
Timeframe: Intra-op until 24 hours post-partum.

Uterotonic Doses

Total number of uterotonic doses including methylergonovine, carboprost and misoprostol. (NCT02509312)
Timeframe: 0 - 24 hours post-partum

Change in Pain Score Post-Cesarean Delivery

Pain score post-Cesarean Delivery using 11-point numerical rating scale (NRS): 0-10 where 0 is no pain and 10 is the worst pain imaginable (NCT02509312)
Timeframe: Up to 24 hours post-cesarean delivery

Percentile Change in Diastolic Blood Pressure (DBP) at 6,12, and 24 Hours

Percentile change in diastolic Blood Pressure at 6,12, and 24 hours for each patient's baseline defined by immediate post-op PACU vitals. (NCT02509312)
Timeframe: 0 - 24 hours post-partum

Percentile Change in Systolic Blood Pressure at 6,12, and 24 Hours

Percentile change in Systolic Blood Pressure at 6,12, and 24 hours for each patient's baseline defined by immediate post-op PACU vitals. (NCT02509312)
Timeframe: 0 - 24 hours post-partum

Reviews

1 review available for ketorolac and Pregnancy

Trials

18 trials available for ketorolac and Pregnancy

Other Studies

14 other studies available for ketorolac and Pregnancy